Replies to post #220258 on Biotech Values

[GrthzGd]

Oh well, there's always NASH.

[vinmantoo]

The total amount spent on HCV is a fraction of what it was a mere 3 years ago. It will have to determined if the patient pool is drying up or whether Abbve's pricing model decimated this market.

You can't be serious about the patient pool drying up. As far as pricing, I would venture that some small price rises might be in the near future for both ABBV and GILD.